Log In
Print
BCIQ
Print
Print this Print this
 

Xopenex, Xopenex HFA, levalbuterol

  Manage Alerts
Collapse Summary General Information
Company Dainippon Sumitomo Pharma Co. Ltd.
DescriptionSingle isomer of albuterol delivered via hydrofluoroalkane (HFA) metered-dose inhaler (MDI)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat bronchospasm; Treat bronchospasm in patients with chronic obstructive pulmonary disease (COPD); Treat or prevent bronchospasm in adults, adolescents and children 4 years of age or older with reversible obstructive airway disease; Treat or prevent bronchospasm in children 4 to 11 years of age
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today